Xenon Pharmaceuticals XENE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$102.3M+2.8% | -$105.26M-15.8% | -$90.9M-7.3% | -$84.71M-30.2% | -$65.05M+1.0% | ||
| $587K-3.9% | $611K-4.7% | $641K+1.4% | $632K-4.1% | $659K-1.1% | ||
| $16.89M+19.7% | $14.12M+3.0% | $13.71M-0.1% | $13.71M+12.6% | $12.17M-10.5% | ||
| $447K+140% | -$1.11M-58.9% | -$701K-312% | -$170K+86.0% | -$1.21M+85.9% | ||
| -$1.8M-156% | $3.19M-39.0% | $5.23M+502% | $869K+123% | -$3.78M-161% | ||
| $1.48M— | —— | $3.37M-38.5% | $5.49M+492% | $926K-58.5% | ||
| $47K+14.6% | $41K— | —— | —— | $0— | ||
| $338K+1.2% | $334K+1.2% | $330K+0.9% | $327K+1.6% | $322K+0.9% | ||
| -$349K-4.2% | -$335K+0.6% | -$337K-6.0% | -$318K-3.6% | -$307K+3.5% | ||
| -$205K— | —— | -$283K+96.3% | -$7.56M-205% | $7.18M+1,212% | ||
| -$88.9M-9.1% | -$81.48M-13.6% | -$71.75M-11.7% | -$64.23M-4.2% | -$61.65M-13.4% | ||
| $133K-58.2% | $318K+13.2% | $281K+79.0% | $157K+265% | $43K-94.5% | ||
| -$407.28M-750% | $62.7M+62.7% | $38.53M-53.2% | $82.26M+138% | $34.51M-65.0% | ||
| $5.49M+296% | $1.39M-41.3% | $2.36M+3,531% | $65K-94.4% | $1.15M+2,349% | ||
| $843.01M+643% | $113.54M+4,711% | $2.36M+3,531% | $65K-94.4% | $1.15M-90.5% | ||
| -$130K— | —— | —— | $632K+1,088% | -$64K+94.5% | ||
| $346.7M+266% | $94.65M+407% | -$30.87M-265% | $18.72M+172% | -$26.06M— | ||
| —— | —— | $1.65M— | —— | —— | ||
| $204K+227% | -$161K-368% | $60K-71.4% | $210K+215% | -$182K+67.7% | ||
| -$349K-4.2% | -$335K+0.6% | -$337K-6.0% | -$318K-3.6% | -$307K+3.5% | ||
| -$205K— | —— | -$283K+96.3% | -$7.56M-205% | $7.18M+1,212% | ||
| $1.48M— | —— | $3.37M-38.5% | $5.49M+492% | $926K-58.5% | ||
| $338K+1.2% | $334K+1.2% | $330K+0.9% | $327K+1.6% | $322K+0.9% | ||
| —— | —— | —— | —— | —— | ||
| $837.53M+2,887% | $28.04M0.0% | $28.04M0.0% | $28.04M0.0% | $28.04M+828% | ||
| —— | $5.25M0.0% | $5.25M0.0% | $5.25M0.0% | $5.25M+153% | ||
| $17.64M— | —— | $2.24M-72.8% | $8.24M+295% | $2.09M-27.2% | ||
| -$349K-4.2% | -$335K+0.6% | -$337K-6.0% | -$318K-3.6% | -$307K+3.5% | ||
| $439K+1.2% | $434K-0.2% | $435K+2.4% | $425K+1.2% | $420K-1.6% | ||
| —— | —— | —— | —— | —— | ||
| -$89.03M-8.8% | -$81.8M-13.6% | -$72.03M-11.9% | -$64.39M-4.4% | -$61.7M-11.8% | ||
| -$89.03M-8.8% | -$81.8M-13.6% | -$72.03M-11.9% | -$64.39M-4.4% | -$61.7M-11.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Xenon Pharmaceuticals's cash flow data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.